Dundalk, IrelandJune 8, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its Ireland site has won three awards at the 2026 Ireland Life Sciences Industry Awards, including the highest honor, “Overall Excellence in Life Sciences,” as well as “Life Sciences Team of the Year” and “Outstanding Contribution Award.” The Ireland Life Sciences Industry Awards are among the most influential industry accolades in the Irish life sciences sector, recognizing companies and teams that have achieved outstanding excellence in innovation, operational excellence, and industry leadership in pharmaceuticals, biotechnology, medical devices, and related fields.
In this year’s awards, WuXi Biologics’ Ireland site was shortlisted in eight categories, covering areas such as innovation, operational excellence, strategic partnerships, laboratory management, corporate social responsibility, and diversity and inclusion. Ultimately, the WuXi Biologics Biologics Manufacturing Science and Technology (MSAT) team won the “Life Sciences Team of the Year” award for its outstanding performance in biologics science and technology innovation, technology transfer, operational excellence, and high-quality delivery. It also stood out among all category winners to claim the “Overall Excellence in Life Sciences” award, fully demonstrating the team’s remarkable achievements in advancing advanced biologics manufacturing and operational management innovation.
These awards further validate WuXi Biologics’ Ireland site’s leading position in biologics, technological innovation, operational excellence, and sustainable development. As a key component of WuXi Biologics’ global manufacturing network, the Ireland site continues to provide global partners with high-quality, efficient, and sustainable biologics development and commercial manufacturing solutions, accelerating the delivery of innovative therapies to patients worldwide.
Since commencing operations, WuXi Biologics’ Ireland site has rapidly developed into one of Europe’s leading commercial biologics manufacturing bases. The site features industry-leading single-use manufacturing technology and large-scale commercial manufacturing platforms, earning international recognition for its outstanding achievements in operational excellence, innovation capabilities, and sustainable development performance. In recent years, the site has achieved multiple key regulatory and operational milestones, including GMP certification from Ireland’s Health Products Regulatory Authority (HPRA) and commercial manufacturing certification from the European Medicines Agency (EMA).
Previously, WuXi Biologics’ Ireland site also received honors such as the International Society for Pharmaceutical Engineering (ISPE) 2023 Facility of the Year Award and the 2025 “Operational Excellence in Life Sciences Award.” Winning three significant honors at the Life Sciences Industry Awards further underscores the comprehensive strength of WuXi Biologics’ Ireland site in biologics, operational management, and industrial innovation, as well as its important role as a strategic hub for global biologics manufacturing.
Currently, WuXi Biologics has operations in China, the United States, Ireland, Germany, and Singapore, with a total of 24 drug substance (DS) manufacturing facilities and 18 drug product (DP) manufacturing facilities in operation. Leveraging its “Global Dual Sourcing Strategy,” the company’s global network is committed to providing clients with integrated dual-source supply covering DS and DP, spanning the entire lifecycle from clinical development to commercial-scale manufacturing. As of the end of 2025, WuXi Biologics has successfully completed 46 global regulatory authority inspections, including 22 from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), all with zero critical findings and zero data integrity issues.
About WuXi Biologics
WuXi Biologics (Stock Code: 2269.HK) is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). Through its open-access, integrated biologics capability and technology platform, the company provides comprehensive end-to-end services to help partners discover, develop, and manufacture biologics, from concept to commercial production, accelerating global biologics R&D processes, reducing R&D costs, and benefiting patients worldwide*.
Leveraging its global network connecting China, the United States, Ireland, Germany, and Singapore, WuXi Biologics brings together over 13,000 employees, including industry experts and scientists in biologics R&D and manufacturing, technological innovation, and operational excellence. With its leading technology platforms and deep expertise, the company provides efficient, cost-effective, and scalable biologics solutions tailored to meet client needs at different stages. Additionally, the company systematically integrates digital capabilities and infrastructure into the full value chain of biologics R&D, laboratory operations, and manufacturing, transforming data, computing, and predictive capabilities into more transparent client collaboration experiences, faster R&D processes, smarter operational management, and more efficient production delivery. As of the end of April 2026, WuXi Biologics had a total of 982 integrated projects in R&D and manufacturing for clients, including 78 Phase III clinical projects and 25 commercial manufacturing projects, with complex molecule projects accounting for over 50% of the company’s total project portfolio.
WuXi Biologics regards sustainable development as the cornerstone of long-term business growth. The company continuously promotes green innovation technologies, providing global partners with advanced end-to-end green CRDMO solutions while achieving outstanding results in ESG. Upholding the concept of creating shared value, the company collaborates with stakeholders to build a sustainable development ecosystem, driving both social value and ecological benefits through responsible operational models, enabling synergistic empowerment across the entire value chain.
For more information, please visit: www.wuxibiologics.com
*Awarded “2026 Biologics CDMO Leadership Award” (Large CDMO Category) (Life Science Connect / Outsourced Pharma)
*Awarded “2026 Best Contract Development and Manufacturing Organization Award” (ABEA)
For more information, please contact